The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes

Journal of Immunotherapy

Volumn 31, Issue 1, 2008, Pages 7-17

  Adair, Sara J ^a   Carr, Tiffany M ^a   Fink, Mitsú J ^a   Slingluff Jr , Craig L ^a   Hogan, Kevin T ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Cancer testis antigen; CTL; Epitope; Immunotherapy

Indexed keywords

CANCER TESTIS ANTIGEN; EPITOPE; HLA A1 ANTIGEN; HLA A2 ANTIGEN; HLA A3 ANTIGEN; HLA B7 ANTIGEN; HLA B8 ANTIGEN; LEUCYLLEUCYLLEUCYLARGINYLLEUCYLGLUTAMYLCYSTEINYLASPARAGINYLVALINE; PROTEIN TAG 1; PROTEIN TAG 2A; PROTEIN TAG 2B; PROTEIN TAG 2C; SERYLLEUCYLGLYCYLTRYPTOPHANYLLEUCYLPHENYLALANYLLEUCYLLEUCYLLEUCINE; CONTACTIN 2; HLA ANTIGEN CLASS 1; NERVE CELL ADHESION MOLECULE; PEPTIDE FRAGMENT; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ALGORITHM; AMINO ACID SEQUENCE; ANTIGEN FUNCTION; ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER CELL; COLON CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LUNG CANCER; MELANOMA CELL; NORMAL HUMAN; OVARY CANCER; PHARYNX CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TONGUE CANCER; BRAIN TUMOR; BREAST TUMOR; CHEMISTRY; COLON TUMOR; CYTOTOXICITY TEST; DENDRITIC CELL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LUNG TUMOR; METABOLISM; MONONUCLEAR CELL; NEOPLASM; OVARY TUMOR; PATHOLOGY; TONGUE TUMOR; TUMOR CELL LINE; UTERINE CERVIX TUMOR;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL ADHESION MOLECULES, NEURONAL; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-A2 ANTIGEN; HUMANS; LEUKOCYTES, MONONUCLEAR; LUNG NEOPLASMS; NEOPLASMS; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS; PHARYNGEAL NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TONGUE NEOPLASMS; UTERINE CERVICAL NEOPLASMS;

EID: 40749086413     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318159f797     Document Type: Article

References (32)

1. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329-360.
2. Lollini PL, Cavallo F, Nanni P, et al. Vaccines for tumour prevention. Nat Rev Cancer. 2006;6:204-216.
3. Ostrand-Rosenberg S, Pulaski BA, Clements VK, et al. Cell-based vaccines for the stimulation of immunity to metastatic cancers. Immunol Rev. 1999;170:101-114.
4. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother. 2005;54:721-728.
5. Coulie PG, Connerotte T. Human tumor-specific T lymphocytes: does function matter more than number? Curr Opin Immunol. 2005;17:320-325.
6. Parmiani G, Castelli C, Rivoltini L, et al. Immunotherapy of melanoma. Semin Cancer Biol. 2003;13:391-400.
7. Parmiani G, Castelli C, Dalerba P, et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst. 2002;94:805-818.
8. Weber J. Peptide vaccines for cancer. Cancer Invest. 2002;20:208-221.
9. Nagorsen D, Scheibenbogen C, Marincola FM, et al. Natural T cell immunity against cancer. Clin Cancer Res. 2003;9:4296-4303.
10. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother. 2005;54:187-207.
11. Ohnmacht GA, Marincola FM. Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma. J Cell Physiol. 2000;182:332-338.
12. Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today. 2000;21:455-464.
13. Slingluff CL Jr, Colella TA, Thompson L, et al. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol Immunother. 2000;48:661-672.
14. Seliger B, Cabrera T, Garrido F, et al. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol. 2002;12:3-13.
15. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 1999;10:281-287.
16. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol. 1997;9:684-693.
17. Castelli C, Rivoltini L, Andreola G, et al. T-cell recognition of melanoma-associated antigens. J Cell Physiol. 2000;182:323-331.
18. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immunity. 2004;4:1.
19. Chomez P, De Backer O, Bertrand M, et al. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 2001;61:5544-5551.
20. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 1997;94:1914-1918.
21. Hogan KT, Coppola MA, Gatlin CL, et al. Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T lymphocyte reactivity to melanoma. Cancer Res. 2004;64:1157-1163.
22. Yamshchikov G, Thompson L, Ross WG, et al. Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluations. Clin Cancer Res. 2001;7:909s-916s.
23. Rammensee HG, Bachmann J, Emmerich NPN, et al. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999;50:213-219.
24. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 1994;152:163-175.
25. Feuerstein B, Berger TG, Maczek C, et al. A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use. J Immunol Methods. 2000;245:15-29.
26. Lu J, Celis E. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res. 2002;62:5807-5812.
27. Lu J, Celis E. Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes. Cancer Res. 2000;60:5223-5227.
28. Greenberg PD, Cheever MA. Treatment of established tumor by adoptive immunotherapy with specifically immune T cells. Surv Immunol Res. 1985;4:283-296.
29. Hogan KT, Eisinger DP, Cupp SB III, et al. The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene. Cancer Res. 1998;58:5144-5150.
30. Zendman AJ, de Wit NJ, van Kraats AA, et al. Expression profile of genes coding for melanoma differentiation antigens and cancer/testis antigens in metastatic lesions of human cutaneous melanoma. Melanoma Res. 2001;11:451-459.
31. Zendman AJ, Ruiter DJ, Van Muijen GN. Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol. 2003;194:272-288.
32. Mori M, Beatty PG, Graves M, et al. HLA gene and haplotype frequencies in the north american population: the national marrow donor program donor registry. Transplantation. 1997;64:1017-1027.